INTRODUCTION
The desirable process of hemostasis and the undesirable phenomena of thromboses are unequivocally consequences of the generation of thrombin by the prothrombinase complex. This stoichiometric complex of factor Xa and factor Va assembled on a platelet membrane converts membrane-bound prothrombin into its active products by two sequential peptide-bond cleavages. The functionality and durability of the prothrombinase complex is subject to multiple regulatory processes which may enhance or eliminate its function. Factor Va an essential component of prothrombinase, is both produced and destroyed by proteolytic events. The absence or dysfunction of factor Va leads to hemorrhagic disease; while excessive longevity of the active species is associated with thrombosis.
Factor V is thus required for a good outcome (Dr. Jeckyll) but also is a potential source of disaster (Mr.
Hyde). In this review, we will summarize the current state of knowledge with respect to the good and the bad aspects of factor V functionality and durability.
II. BACKGROUND
The factor Va molecule is generated by cleavage of its precursor factor V. It contributes to the blood clotting reaction by binding with factor Xa on a membrane surface to form the prothrombinase complex. This complex is the essential activator of prothrombin to thrombin during the blood clotting process and, effectively increases the activity of factor Xa by five orders of magnitude.
Factor V was discovered by Paul Owren in 1943 when, using relatively primitive technology, he was able to deduce the existence of a fifth component required for fibrin formation which he named "factor V", thus beginning the era of Roman numerology for coagulation factors. This work published in Lancet after War World II (1) also identified the procofactor nature of factor V and the requirement for its activation by thrombin as well as its participation in the generation of thrombin. Dr. Owren's
For personal use only. on . by guest www.bloodjournal.org From Updated MK 6-26-02 C:\Inetpub\ftproot\upload\598df6ec119ce94b014\$ASQReviewforFa ctorVinBlood_very_finalrev_MK062602.doc 3 work defined factor V as the activity in normal plasma that corrected the prothrombin time (PT) of the plasma of a patient with factor V deficiency (1, 2) . Following a long period of controversy, factor V was isolated in 1979 (3) (4) (5) (6) . The isolation established the "biochemistry" period of blood clotting complexes and launched the paradigm of membrane bound complexes contributing to the blood clotting process.
Human plasma factor V circulates at a concentration of 20 nM, as a large single chain procofactor with a M r 330,000 (4) (5) (6) . In addition, approximately 20% of the total human factor V found in whole blood is contained in the platelet -granules (7) . The significance of platelet factor V is underscored by either patients with a deficiency in platelet factor V (Factor V Quebec) who exhibit a bleeding diathesis or by asymptomatic individuals with potent circulating inhibitory factor V antibodies that do not have access to platelet factor V (8) (9) (10) (11) (12) (13) . The platelet fraction of factor V is both synthesized in the megakaryocyte and absorbed from plasma and sequestered in the -granules (14) . Platelet factor V is partially fragmented, stored in association with multimerin and secreted during platelet activation. It requires further proteolytic activation to fully participate in prothrombinase function (15) (16) (17) (18) (19) (20) .
The binding protein multimerin is found in platelets and endothelial cells and appears to be a carrier for platelet factor V. It contains an Arg-Gly-Asp-Ser motif as well as an epidermal growth factor domain (19, 20) . The multimerin monomers are linked via inter-chain disulfide bonds, to produce one of the largest proteins found in platelets with a mass exceeding M r~ 1,000,000. Following platelet activation, both factor V and multimerin are released and dissociate from one another (19, 20) .
The physiological significance of factor Va for clot formation is clearly demonstrated in mice where complete deficiency of factor V results in massive hemorrhage and death (21) . However, humans who are deficient in plasma factor V (< 2% factor V clotting activity) while rare (prevalence of 1 in one million) show variable bleeding tendencies (11, 12, 22) . The physiological relevance of factor Va in
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Updated MK 6-26-02 C:\Inetpub\ftproot\upload\598df6ec119ce94b014\$ASQReviewforFa ctorVinBlood_very_finalrev_MK062602.doc 4 the pathology of thrombosis is assured because of case reports of familial thrombophilia associated with factor V mutations and defects in the protein C pathway (23, 24) . In this review, we will describe the structure, activation, function and inactivation of factor V, and discuss pathological states associated with genetic mutations of the factor V molecule.
III. STRUCTURE
The 80 kb factor V gene is located on chromosome 1 at q21-25 (25) and contains 24 introns.
Following transcription it gives rise to a 6.8kb mRNA (25) (26) (27) (28) . Synthesis of factor V has been demonstrated by bovine aortic endothelial cells (29) , a human hepatocarcinoma cell line HepG2 (30) , and by human and guinea pig megakaryocytes (31) . The liver appears to be the principal source of factor V in plasma and platelets (7) .
The human factor V molecule (Fig.1A) is secreted after pre-pro-peptide processing as a 2196 amino acid protein. The molecule is composed of triplicated A domains, a B domain and duplicated C domains (26) (27) (28) . The A domains are homologous to those found in plasma ceruloplasmin and factor VIII, each of which are members of a copper binding family (32) . The C domains are homologous to the slime mold protein discoidin (26) . The B domain is poorly conserved among the various species of factor V that have been studied. The B domain of human factor V which is ultimately released in the form of two heavily glycosylated fragments of M r 150,000 and 71,000 contain 44 semi-conserved repeats of the form Asp-Leu-Ser-Gln -Thr-Thr/Asn-Leu-Ser-Pro. This highly glycosylated region also contains two conserved repeats of 17 amino acid each (26) .
The factor V molecule undergoes multiple posttranslational alterations including sulfation, phosphorylation and glycosylation (Fig.1A , Table 1 ) (33) (34) (35) (36) (37) (38) (39) . Inhibition of Tyrosine sulfation by sodium chlorate results in a cofactor molecule with 1/5 th the activity of the native molecule. Thus, sulfation appears important for factor V/Va function (34, 35) . Factor Va is also phosphorylated by a membrane- (36) (37) (38) . Phosphorylation of the heavy chain of factor Va at Ser 692 increases the rate of inactivation of the cofactor by activated protein C (38) .
The platelet CKII responsible for factor Va phosphorylation is composed of and subunits. The CKII subunit is the product of an intronless gene located on chromosome 11 (40) . The factor V molecule has multiple potential N-linked glycosylation sites in the B region and on the heavy and light chains that influence secretion (Fig.1A , Table 1 ) (26, 39) . The N-linked carbohydrate chains on the factor V molecule include a complex array ranging from biantenary, bisialyted chains without fucose addition to tetrantenary, tetrasialyated with multiple fucose attachments (39) .
For Factor V has 19 cysteine residues (see Table 1 for locations, and Fig.1A ) (41, 42) . Five of the cysteines are present as free -SH while the remaining fourteen are involved in disulfide bridges forming several loops: three 26 amino acid residue -loops are present, one in each "A" domain; the "A1" and "A2" domains each contain one -loop each of which is composed of 82 amino acids (Table   1) ; two -loops which are composed of 154 and 155 residues and each with a free -SH represent the "C1" and "C2" domains (Fig.1A) . The cysteine residue at position 539 appears to be very reactive. Models of the A domains of the molecule based upon the coordinates of ceruloplasmin have been described (43) (44) (45) , however, these hypothetical models of factor Va domains should be only provisionally interpreted until the true crystal structure of factor Va becomes available. The crystal structures of the recombinant C 2 domain of the molecule has recently been reported (46) . Bovine factor Va has been crystallized (47) and a preliminary account of the crystal structure of bovine factor Va has been reported. 
IV. ACTIVATION
Factor V is the inactive precursor of factor Va that contributes factor Xa receptor and catalytic effector functions to prothrombinase. The complex formation between factor Xa and factor Vamembrane to form prothrombinase increases the rate at which prothrombin is converted to -thrombin by 300,000-fold relative to the rate of the reaction catalyzed by factor Xa acting alone (48) . The procofactor is activated by a number of proteases including thrombin, factor Xa and (transiently) by plasmin. The thrombin cleavage is the most significant with respect to the biological function of the molecule and occurs as an early event during the blood coagulation process (49) (50) (51) (52) . (53) . The excised B region dissociates as two fragments of M r 71,000 and 150,000
(residues 710-1018 and 1019-1545 respectively) (Fig.1B) . The human factor Va heterodimer is composed of a heavy chain of M r 105,000 and a light chain of M r 74,000 (4) (5) (6) 26) , with the non-covalent association requiring divalent metal ions (Fig.1B ) (53) . The heavy chain (residues 1-709) is composed of two "A" domains (residues 1-303, and 317-656) (26, 27) , connected by a region rich in basic amino Single chain factor V does not bind factor Xa. Thus, the activation of factor V to factor Va is essential to its biological function. During tissue factor initiated blood coagulation thrombin generation can be divided into two phases; an initiation phase during which very small amounts of thrombin are produced (~ 1%, 5nM) and clotting is observed. During a subsequent propagation phase 700-900 nM thrombin is produced (49, (54) (55) (56) . The identity of the initial activator of factor V has been a subject of controversy. While factor Xa-phospholipid, thrombin and plasmin are all capable of activating factor V to factor Va, the kinetic evaluation of tissue factor initiated blood clotting reactions
show that the initial activator of factor V is -thrombin which is initially produced by factor Xa and phospholipid during the initiation phase of the blood coagulation process (49, 51, 52, (54) (55) (56) . While factor Xa-phospholipid is an effective activator of factor V, the concentrations of factor Xa, which exist during the initiation phase of coagulation, are insufficient to explain the activation of factor V that is observed. It is noteworthy that factor Va function is usually measured by its ability to contribute tothrombin generation. Thus, bioassays of factor V/Va depend upon clotting, which requires the generation of -thrombin and thus the presence of both factor Va and factor Xa. Since factor Xa will itself activate factor V the relative concentration of the procofactor (intact factor V) cannot be reliably analyzed in an activity-based assay. Plasmin will both activate and inactivate factor V and these processes may contribute to the pathology of thrombosis (57) (58) (59) (60) .
Substrates for thrombin include platelets, fibrinogen, factor XI, factor V, factor VIII, factor VII and factor XIII. During the process of prothrombin activation by prothrombinase, two forms of thrombin are produced, meizothrombin and -thrombin (61) (62) (63) (64) (65) . with respect to whether -thrombin or meizothrombin is the activator of factor V. Recent data obtained using both natural and recombinant -thrombin and meizothrombin suggest that the kinetic activation of factor V is more favorable through the -thrombin mechanism. In either case the fully active factor Va ultimately depends upon cleavage at residue Arg 1545 , which liberates the light chain of the cofactor.
V. FUNCTION a) Cofactor for factor Xa in prothrombinase
The membrane-binding site of the factor V molecule, which is crucial to its function, appears to be contributed by elements of the C2 and A3 domains contained within the light chain of the molecule (66) (67) (68) (69) (70) . The binding of the light chain to a membrane surface involves both electrostatic and hydrophobic interactions with anionic/neutral membranes and penetration of the molecule into the membrane bilayer (66) (67) (68) (69) (70) (71) . The hydrophobic binding site of factor Va located on the middle portion of the A3 domain, is suggested to interact with phospholipid and penetrate into the bilayer (66) (67) (68) 71) . The binding site of the cofactor located on the C2 domain of factor Va and reported to interact with anionic phospholipid was found to be exposed on the surface of the molecule as expected for an hydrophilic amino acid sequence (69, 70, 72, 73) . Two recent studies using recombinant factor V and the factor V C2
domain have demonstrated that most of factor V autoantibody inhibitors are directed to the C1-C2 domain of factor V and interfere with its binding to phosphatidyl-serine containing membranes (72, 73) .
Kim et al using alanine-scanning mutagenesis demonstrated that several amino acid substitutions at the COOH-terminus of the light chain resulted in molecules with impaired binding to phosphatidyl serine (72) . Since proper interaction of the cofactor with the membrane surface is required for the expression of factor Va cofactor activity, it must be concluded that these residues located at the carboxyl-terminal portion of factor V, are critical for the interaction of the activated molecule with the cell surface.
Overall the data suggest that initial rapid factor Va-membrane interaction is most likely first mediated through the anionic lipid-binding domain on the C2 domain. Following this diffusion rate limited interaction (74) , a hydrophobic interaction, potentially involving the A3 domain of the molecule (66) (67) (68) tightly anchors the molecule to the membrane core (71) . Binding and penetration of the molecule into the membranes results in a stable, high affinity (K d~2 .5 nM) factor Va-phospholipid interaction (66) .
The physiologically relevant membranes for blood coagulation are provided by platelets and vascular cells (75) (76) . The membranes of these cells are lipid-protein complexes composed principally of phosphatidyl serine, phosphatidyl choline and phosphatidyl ethanolamine (77) (78) (79) . The selective qualities associated with cell binding sites for prothrombinase remain poorly understood.
A fundamental contribution of factor Va to prothrombinase function is the retention of factor Xa on the membrane surface. Stopped-flow reaction kinetic data show that both factor Va and factor Xa interact with phosphatidyl-choline phosphatidyl-serine vesicles (PCPS vesicles) at diffusionally controlled rates (10 7 -10 8 M -1 sec -1 ) (74, (80) (81) (82) (83) . However, factor Xa has an affinity (K d ) for membranes of approximately 0.1 µM and this corresponds to a dissociation rate constant of approximately 3.3 sec -1 .
As a consequence, the duration of retention of factor Xa alone on a membrane is short lived even though the membrane association process is rapid. Biologically relevant factor Xa concentrations probably never exceed 0.15µM, however, membrane dependent complex assembly occurs such that membrane-bound factor Xa binds tightly to membrane-bound factor Va. factor Xa effectively increases the affinity of the enzyme for the phospholipid bilayer (74, 81) . The two polypeptide chains of the factor Va molecule are also in dynamic self association with a dissociation constant in the range of 3.6 nM (53) . Thus, at the physiological concentrations that occur early during the coagulation reaction, dissociation (and inactivation) of the factor Va molecule can also occur. The factor Va-factor Xa protein-protein interaction is relatively weak in the absence of a membrane surface (K d~0 .8 µM) and probably not relevant at biological concentrations (84) . When coupled with the interactions of both proteins with the membrane, both the light and heavy chains of factor Va interact with factor Xa; each contributing to dissociation constants in the mM range resulting in a tight association of the two proteins (K d~1 nM) when coupled with membrane binding (80, 81, 85) .
The membrane bound factor Va-factor Xa complex cleaves membrane-bound prothrombin to produce -thrombin only in the local environment of membrane-bound complex (principally the immobilized activated platelet membrane surface). As a consequence of the common membrane binding of both substrate and enzyme, the effective K m for prothrombin activation is decreased by two orders of magnitude. Owing to alterations in factor Xa, prothrombin or both, the k cat for the membrane localized reaction is increased by three orders of magnitude. As a consequence, the amount of prothrombin produced by the prothrombinase complex formed on an appropriate membrane is increased by five orders of magnitude compared to the activation of prothrombin by factor Xa alone.
Thus, the amount of -thrombin formed in one minute by the prothrombinase complex would take six months if factor Xa acted alone. The process of prothrombinase activation of prothrombin is altered from that observed with factor Xa alone bound to a membrane surface. Prothrombinase cleaves prothrombin initially at Arg 320 to yield meizothrombin, with subsequent cleavage at Arg 271 yieldingthrombin and fragment 1•2 (80, 86) . These two products continue to self-associate in a non-covalent manner (K d ~ 10 -8 M) (86) . In contrast, factor Xa-membrane cleaves prothrombin first at Arg 271 to give (87, 88) . As a consequence, the data suggest that all intermediates leading to -thrombin stay attached to the prothrombinase complex until the end products ( -thrombin and F 1.2) are released in solution.
b) Cofactor for the APC/protein S complex in the inactivation of factor VIII
Dahlbäck and colleagues reported that the intact procofactor, single chain factor V, can act as a cofactor, contributing to the acceleration of inactivation of factor VIIIa by the APC/protein S complex (89) . Our laboratory demonstrated that factor V can accelerate the rate of factor VIII inactivation by APC, only when protein S was present (90) . Under the conditions employed factor V was completely cleaved by APC early during the inactivation reaction, and before 10-20% factor VIII activity was lost (90) . APC-treated, membrane-bound factor V as well as -thrombin activated factor Va (inclusive of the B domain) produced an increase in the rate of inactivation of factor VIII by the APC/protein S complex by two fold. In contrast, purified factor Va (lacking the B domain) even at high concentrations does not show any cofactor effect on the rate of the inactivation of factor VIII, (± protein S) (90) . These observations suggest that the B region fragments of factor V may be responsible for the cofactor effect of factor V during the inactivation of factor VIII by the APC/protein S complex.
For
VI. INACTIVATION
Activated protein C (APC) down-regulates -thrombin generation and as a consequence the coagulation process by proteolytically inactivating factor Va and factor VIIIa the cofactors of prothrombinase and intrinsic factor Xase respectively (91) . Under physiological conditions, inactivation of factor VIIIa occurs spontaneously in the absence of APC following dissociation of its A2, domain;
as a consequence, APC appears not to be essential for factor VIIIa inactivation (90, 92, 93) . In contrast, proteolytic cleavage of factor Va by APC is required for its inactivation (94) (95) (96) .
Protein C is activated to APC by -thrombin in the presence of the vascular cofactor thrombomodulin (97, 98) . APC binds to the light chain of factor Va, in a competitive manner with factor Xa (99) (100) (101) (102) . Conversely, factor Xa impairs APC cleavage and inactivation of the cofactor (101, 102) . Thus, APC provides inhibition of coagulation by non-covalent competition with factor Xa and by cleavage and inactivation of factor Va (94, 95, (100) (101) (102) . APC cleaves human factor Va heavy chain at Arg 506 , Arg 306 and Arg 679 with the kinetic order of these cleavages generally as specified (Fig.1A and Fig.1C upper part) (95, 100) . The cleavages at Arg 506 and Arg 306 are influenced by a membrane surface with the cleavage at Arg 306 being virtually dependent upon the presence of an anionic-phospholipid containing membrane (95) . Following cleavage at Arg 506 , the resulting cofactor (factor Va R506 ) displays lessened apparent affinity for factor Xa (103) . As a consequence, prothrombinase with factor Va R506 has reduced efficiency in catalyzing the activation of prothrombin to -thrombin prolonging the prothrombin time, however, factor Va R506 is still "active" providing binding and effector functions for factor Xa, albeit reduced.
During a one-stage plasma-clotting assay, the endpoint clot is produced when only approximately 10% of the total factor V present in plasma has been activated, approximately 7 pM factor Xa is available, and less than 2% of the prothrombin activation process has occurred (52, 55) .
When measured in a clotting assay, most of the activity of factor Va is perceived to be lost by cleavage at Arg 506 , because cleavage at Arg 506 reduces the apparent affinity for factor Xa, and the binding of factor Va R506 to limiting amounts of factor Xa available becomes a major determinant of the "activity" of the factor Va molecule (104) . However, when the reaction is measured at saturating concentrations of factor Xa, the cleavage at Arg 506 of factor Va leads to the loss of only 25-40% of the factor Va cofactor activity. In contrast, cleavage at Arg 306 leads to the ultimate inactivation of factor Va (95, 104) . Physical studies using ultracentrifugation and light scattering show that the products of cleavage of factor Va by APC at Arg 306 and Arg 506 dissociate to produce fragments, which correspond to the A 1 domain of the molecule, non-covalently associated with the A3C1C2 (light chain), and fragments A2 N and A2 C which correspond to the amino and carboxyl termini of the A2 domain (Fig.1C , upper part) (103) . The inactivation rate of factor Va when explored as a function of APC concentration becomes independent of enzyme concentration, a clear signal that the final inactivation step involves not only cleavage but also dissociation of the A2 N and A2 C fragments from the rest of the molecule (100, 103) . The human procofactor, factor V, is also inactivated by APC, but only when bound to a membrane-surface.
Human factor V is inactivated by cleavages at Arg 306 , Arg 506 , Arg 679 , and Lys 994 . In this instance, cleavage at Arg 306 which occurs first appears to be the sole requirement for inactivation (95) .
In studies of the ability of endothelial cells to complement the activation of protein C and the inactivation of factor Va, an APC-independent cleavage was observed which resulted in an inactive product (104, 105) . In the presence of endothelial cells, -thrombin appears to cleave factor Va at Arg 643 resulting in an inactive molecule (Fig.1C, lower part) . The product of this cleavage, initially observed in vitro, was also observed in vivo in studies of blood exuding from microvascular wounds in the skin surface (106) . The mechanism of factor Va inactivation because of Arg 643 -mediated cleavage is unclear but appears to be the result of reduced affinity between the two chains of factor Va (105) (Fig.1C, lower For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Updated MK 6-26-02 C:\Inetpub\ftproot\upload\598df6ec119ce94b014\$ASQReviewforFa ctorVinBlood_very_finalrev_MK062602.doc part). Plasmin has also been shown to inactivate factor Va with the cleavages being dependent upon the presence of a membrane-surface (58, 59) . (Fig.1A ) (59) .
VII. PATHOLOGY a) Hemorrhagic Pathology: Parahemophilia
Factor V deficiency is extremely uncommon occurring either because of a homozygous inheritance or because of a combination of defective alleles. However, humans with factor V deficiency are alive (8, 11, 12) while, in mice, the total lack of factor V is not consistent with survival (21) .
In empirical models conducted with purified reaction components and computer models of the blood coagulation system, -thrombin cannot be generated in the absence of factor V when all inhibitors are present in the reaction system (100, 107, 108) . Conversely, humans with severe truncations in the factor V molecule which do not allow any synthesis of factor V by known conventional mechanisms have been observed to have either manageable or no pathology associated with bleeding. These observations suggest that there may be compensatory mechanisms present in human blood, which either bypass or reduce the need for factor V in generating levels of -thrombin required for survival.
Point mutations in the factor Va gene resulting in abnormal factor V function are associated with amino acid substitutions located on the entire coding region of factor V ( of the protein or in the complete deficiency of factor V if the mutation results in a stop codon in the middle of the reading frame (Table 2) .
b) Defects in the inactivation of factor V/Va associated with thrombosis

APC Deficiency
Mature protein C is composed of several conserved domains each of which is characteristic for the vitamin K-dependent proteins. Human protein C is encoded by an autosomal gene of approximately 10 kb located on chromosome 2q13-14 (109, 110) . Absence of the protein or a defective circulating protein in plasma, which is the result of more that 160 different mutations, has severe consequences for the individuals bearing the mutations (111) . Individuals who are heterozygous for a protein C mutation, resulting in low levels of circulating protein C because one of the two alleles does not produce the normal protein, variably suffer from venous thrombosis (112) . However, homozygous protein C deficiency, characterized by the complete absence of circulating protein C, is a very serious condition with life threatening thrombotic symptoms. This severe condition usually presents immediately after birth, in the form of purpura fulminans with the only remedy being the infusion of protein C (113) (114) (115) .
Congenital APC-Resistance
a.-Factor V
LEIDEN
In 1994 Dahlbäck et al observed that plasma from some individuals with venous thrombosis had a reduced response to APC (23) . When APC is introduced into normal plasma there is a (94, 95, 116) , led to the identification of factor V LEIDEN (117) . This polymorphism occurs as a consequence of a G A substitution at nucleotide 1691 in the factor V gene, leading to the substitution of an arginine by a glutamine at position 506 of the human factor V molecule (117) . Arg 506 is the initial cleavage site for APC on the heavy chain of human factor Va and facilitates the subsequent lipid-dependent inactivation cleavage at Arg 306 (95, 100, 104) . (118) . However, inactivation still proceeds through cleavage at Arg 306 (96, (118) (119) (120) (121) (122) (123) . Since elimination of the latent activity of membrane-bound factor V occurs because of an initial cleavage at Arg 306 , factor V LEIDEN is inactivated by APC at the same rate as normal factor V (118) . Platelet-factor Va and factor Va LEIDEN inactivation by APC proceed at similar rates and are delayed when compared with their plasma equivalents (124, 125) . Thus, on the surface of platelets there is little difference in the inactivation rates of the two molecules, both of which are protected from inactivation. Recently, two groups reported patients with thrombotic disorders that were heterozygous for an amino acid substitution at the Arg 306 cleavage site (126, 127) .
As a consequence of the factor V LEIDEN mutation, the partial loss of activity of the normal factor Va molecule which occurs following cleavage at Arg 506 , resulting in diminished interaction between factor Va and factor Xa is not observed. The pathology of factor V LEIDEN is associated in vivo with thrombotic manifestations, which are observed in both homozygous and heterozygous individuals (128) (129) (130) (131) (132) . Venous thrombosis is more common among those individuals homozygous for the Arg 506 Gln
substitution. Statistical analyses suggest that the relative risk for a thrombotic episode in individuals
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Updated MK 6-26-02 C:\Inetpub\ftproot\upload\598df6ec119ce94b014\$ASQReviewforFa ctorVinBlood_very_finalrev_MK062602.doc heterozygous for factor V LEIDEN is sevenfold higher that the risk for normal individuals (133) . In contrast, homozygous factor V LEIDEN individuals, have a 80-fold higher risk for thrombosis than individuals with the normal factor V gene (132, 133) . No correlation has been observed between arterial thrombosis and the existence of factor V LEIDEN (134) (135) (136) . inactivation by mutation the APC would not be selectively associated with arterial thrombosis. Many studies have shown that the thrombotic risk in homozygous patients carrying the factor V LEIDEN mutation is influenced by other acquired and congenital risk factors but less dramatic than the risk of thrombosis for patients homozygous for protein C and protein S deficiencies (137) (138) (139) (140) (141) .
b-The HR2 haplotype
The factor V allele H1299R (also known as R2 haplotype) is marked by an A to G transition at position 4070 in the factor V gene (142) . This mutation (in the B region) is a marker that co-segregates with several other polymorphisms encoding several amino acid changes in the factor V molecule (142) (143) (144) (145) . It has been reported that individuals carrying the factor V H1299R mutation have mild APCresistance, and an increase in the risk of venous thrombosis. Thus this ensemble of polymorphisms
represents per se a potential thrombotic risk factor (145, 146) . We have recently described a thrombotic family with the R2 haplotype and several symptomatic members (146) . One of these individuals was found to be doubly heterozygous, for the factor V HR2 haplotype and for the Y 1702 C mutation. The latter mutation was shown to be at the origin of factor V deficiency resulting in the absence of circulating normal factor V (146, 147) . Thus, since the factor V allele predicting the Y 1702 C substitution and encoding for a non-R2 haplotype factor V is not expressed at the protein level, the plasma of this patient contains only molecules encoded by the R2 haplotype (147) . This individual had also mild APCresistance and was classified as a "pseudohomozygous" R2 haplotype. We have found in this individual that the factor V molecule that is characterized by the mutations included in the R2
haplotype is resistant to APC inactivation because of impaired cleavage by APC at both, Arg 506 and Arg 306 (147) . These findings suggest the possibility that one or more of the amino acid substitutions, which are predicted by the R2 haplotype, impair factor Va cleavage by APC at Arg 506 /Arg 306 . The patient studied was also carrier of the D 2194 G substitution which is tightly associated with the R2 haplotype, and the most likely candidate for the observed APC-resistance of factor Va. Studies by Kim et al using alanine-scanning mutagenesis suggested that several amino acid residues within the COOH terminal portion of the C2 domain of factor V are crucial for the interaction of the cofactor with phosphatidyl-serine (72) . Among those, the D 2194 A substitution had impaired binding to phosphatidyl-serine and defective cofactor activity. However, the factor V molecule from carriers of the R2 haplotype possesses normal procoagulant activity. The R2 haplotype demonstrate resistance to APC because of impaired cleavage at both Arg 506 and/or Arg 306 (147) . Thus, it is possible that the factor Va mutations surrounding Asp 2194 impair its inactivation by APC.
Acquired APC Resistance
Activated protein C resistance may also be observed with elevated levels of homocysteine (148, 149) . Factor V contains five unpaired cysteines, two in the heavy chain, two in the light chain and one in the B region (41, 42) (Table 1) . These cysteines can incorporate homocysteine at physiologically relevant concentrations associated with hyperhomocysteinemia and as a consequence display a form of acquired APC resistance (150) .
Influence of factor Va on fibrinolysis
Regulation of factor V activity also contributes to the function of the fibrinolytic cascade (151) (152) (153) . A fibrinolysis inhibitor named "thrombin-activatable fibrinolysis inhibitor" (TAFI) is activated by the -thrombin-thrombomodulin complex to generate an enzyme with carboxypeptidase-like activity, which functions by excision of COOH-terminal lysine and arginine residues from plasmin-cleaved fibrin (154) . These desLys fibrin degradation products are poor cofactors for the activation of plasminogen by tPA. Thus, thrombin-activation of TAFI provides a connection between impaired thrombin generation and unstable fibrin clots. During clotting in plasmas deficient in factor VIII, factor IX or factor XI, thrombin generation is reduced versus the normal case. However, while all the fibrinogen is quantitatively converted to fibrin in these deficient plasmas, the clots exhibit a greater tendency toward lysis than do normal clots, since TAFI activation is also impaired by reduced prothrombin activation.
It has been demonstrated that clot lysis is delayed in plasma from individuals homozygous for the factor V LEIDEN mutation (155) . These data suggest that resistance of factor Va LEIDEN to inactivation by APC, which results in sustained -thrombin formation, also results in enhanced activation of TAFI and impaired removal of the fibrin clot. These data also suggest that the enhanced activation of (155, 156) in individuals with hemophila A; producing a more mild hemostatic defect.
VIII. THE POTENTIAL INFLUENCE OF COMBINED PATHOLOGY ASSOCIATED WITH FACTOR V.
a) TFPI and APC
The dynamic process of factor V inactivation by APC is synergistic with the tissue factor pathway inhibitor (TFPI) inhibition during the tissue factor initiated blood coagulation process (157) (158) (159) (160) (161) .
This occurs because the -thrombin activation of factor V is a sequential phenomenon with cleavage at Arg 709 occurring first to produce the heavy chain. However, factor Va activity is associated with cleavage at Arg 1545 , and formation of the light chain, which occurs more slowly. Once cleaved at Arg 709 , the partially activated membrane-bound factor V molecule can be rapidly cleaved by APC at Arg 306 and Arg 506 , leading to inactivation. If the inactivation process is sufficiently vigorous it can occur prior to the formation of the light chain of the molecule, hence factor Va activity is nullified (161) .
These regulatory processes display synergy between the dynamic APC system and the stoichiometric TFPI inactivation system (161) . In vitro experimental data suggested that a combination of factor V LEIDEN and low normal levels of TFPI could produce unregulated generation of thrombin because of the absence of the appropriate synergy between two dynamic regulatory processes (161, 162) . Transgenic mice obtained by crossing mice with reduced levels of TFPI with mice homozygous for factor V LEIDEN resulted in mice with a lethal phenotype with fibrin deposition in multiple organs (163) . The observation of disseminated thrombosis in mice homozygous for the factor V LEIDEN mutation and low levels of TFPI, is in keeping with the hypothesis suggested by in vitro data (162) . Thus, reduced TFPI levels may be a contributor to thrombosis in association with factor V LEIDEN .
b) Hemophilia and factor V LEIDEN
The importance of the timely regulation of factor Va cofactor activity is illustrated by a potentially beneficial effect of factor V LEIDEN for individuals with severe hemophilia A. The net effect of factor VIII deficiency is reduced -thrombin formation rate; conversely, individuals with the factor V LEIDEN mutation have sustained -thrombin formation. Significant differences in pathology between unrelated patients carrying the same factor VIII missense mutations have been reported (164) . While these factor VIII mutations most commonly result in a phenotype characterized by severe bleeding in individuals carrying the normal factor V gene, two hemophiliacs heterozygous for the factor V LEIDEN mutation have been reported who presented with mild/moderate bleeding episodes. More recently an individual with severe hemophilia B (<1% factor IX activity) but heterozygous for the factor V LEIDEN mutation presented with only a mild bleeding diathesis (165) . Since factor Va LEIDEN is inactivated by APC more slowly a hemophiliac patient with the factor V LEIDEN gene may have a milder bleeding syndrome because of the increased durability of prothrombin activation (166) . These data suggest that, the variability in the expression of single defects associated with hemophilia A and B may in part be because of the high frequency of the factor V LEIDEN mutation in the normal population and that hemophiliacs should also be regularly screened for the Arg 506 Gln mutation.
c) Parahemophilia and factor V LEIDEN
A "pseudo-homozygous" APC-resistance, predisposing to thrombosis, may occur as a consequence of the combination of two defects in factor V which are associated with a quantitative reduction in factor V and heterozygous inheritance of the factor V LEIDEN mutation. The main laboratory findings are the presence of a low APC-sensitivity ratio (APC-SR) and low plasma values (167) (168) (169) (170) . In this case the normal factor V allele is silent and only the factor V LEIDEN allele is expressed. As a consequence, the patient who is genetically heterozygous for factor V LEIDEN is phenotypically homozygous for the mutation (170) .
SUMMARY
Overall, factor V can be thought of as a Dr. Jeckyll and Mr. Hyde. Dr. Jeckyll, the good doctor, who provides a useful support for individuals (hemostasis) and Mr. Hyde, the rapacious monster, causes destruction (thrombosis). We need factor V to have a normal blood clotting physiology, however, the unmanaged evolution of factor V activation can cause severe pathology.
However, sometimes Mr. Hyde can abrogate the damage caused by another monster (hemophilia A or B) providing overall a beneficial support to the individual. 167. Simioni P., Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, and Girolami A.
"Pseudo Homozygous" activated protein C resistance due to double heterozygous factor V 
